CASI Pharmaceuticals (NASDAQ:CASI – Free Report) had its price target reduced by HC Wainwright from $12.00 to $6.00 in a research report report published on Wednesday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for CASI Pharmaceuticals’ Q2 2024 earnings at ($0.63) EPS, Q3 2024 […]
StockNews.com initiated coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research note released on Friday morning. The firm issued a hold rating on the biotechnology company’s stock. CASI Pharmaceuticals Stock Performance Shares of CASI Pharmaceuticals stock opened at $3.11 on Friday. CASI Pharmaceuticals has a one year low of $1.85 and […]
StockNews.com assumed coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research report released on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock. CASI Pharmaceuticals Stock Performance NASDAQ CASI opened at $3.61 on Thursday. CASI Pharmaceuticals has a fifty-two week low of $1.85 and a fifty-two week […]
StockNews.com assumed coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research report sent to investors on Saturday. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright increased their price target on CASI Pharmaceuticals from $10.00 to $12.00 and gave the stock a buy rating in a […]
StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research note published on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright raised their price objective on shares of CASI Pharmaceuticals from $10.00 to $12.00 and gave the company a buy rating in […]